Cancer

Explore the complexities of Cancer research and treatment in China’s pharmaceutical industry. At Fineline Info & Tech, we provide reliable data, news, and insights to enhance your understanding and decision-making. Stay informed and stay ahead in the fight against cancer with flcube.com.

IASO Bio Partners with Shenzhen Longuide to Deploy LNP Technology Beyond Oncology – Broadening the Cell Therapy Innovator's Advanced Therapeutics Portfolio
CompanyDeals

IASO Bio Partners with Shenzhen Longuide to Deploy LNP Technology Beyond Oncology – Broadening the Cell Therapy Innovator’s Advanced Therapeutics Portfolio

IASO Biotherapeutics (IASO Bio), a Chinese cell therapy innovator, announced a strategic partnership with Shenzhen Longuide Biopharma Corporation (Longuide), under which IASO Bio will leverage Longuide's lipid nanoparticle (LNP) technology…

China's NHC Issues Working Procedures for Rare Disease Catalogue (2026 Edition) – Expanded Inclusion Criteria and Faster Update Cycle Reshape Drug Access Landscape

China’s NHC Issues Working Procedures for Rare Disease Catalogue (2026 Edition) – Expanded Inclusion Criteria and Faster Update Cycle Reshape Drug Access Landscape

Nxera Pharma Licenses Oral EP4 Agonist NXE0033744 to AbbVie in up to USD 1.47 Billion IBD Deal – Validating the NxWave Discovery Platform

Nxera Pharma Licenses Oral EP4 Agonist NXE0033744 to AbbVie in up to USD 1.47 Billion IBD Deal – Validating the NxWave Discovery Platform

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Bayer's Hyrnuo (Sevabertinib) Wins NMPA Approval in First‑Line HER2‑Mutant NSCLC – Oral TKI Moves Into Treatment‑Naive Patients on 75.3 % ORR from SOHO‑01
CompanyDrug

Bayer’s Hyrnuo (Sevabertinib) Wins NMPA Approval in First‑Line HER2‑Mutant NSCLC – Oral TKI Moves Into Treatment‑Naive Patients on 75.3 % ORR from SOHO‑01

CStone Pharmaceuticals Partners with Kimia Therapeutics to Co‑Develop Potential First‑in‑Class DDR Inhibitor for Solid Tumors – CStone to Lead Phase I in Mainland China and Australia
CompanyDeals

CStone Pharmaceuticals Partners with Kimia Therapeutics to Co‑Develop Potential First‑in‑Class DDR Inhibitor for Solid Tumors – CStone to Lead Phase I in Mainland China and Australia

NMPA Grants Priority Review to Hengrui's Trastuzumab Rezetecan NDA for First‑Line HER2‑Positive Breast Cancer
CompanyDrug

NMPA Grants Priority Review to Hengrui’s Trastuzumab Rezetecan NDA for First‑Line HER2‑Positive Breast Cancer

HutchMed's Orpathys Plus Tagrisso Combination Wins Regulatory Review Acceptance in Europe and Japan for Post‑Tagrisso NSCLC
CompanyDrug

HutchMed’s Orpathys Plus Tagrisso Combination Wins Regulatory Review Acceptance in Europe and Japan for Post‑Tagrisso NSCLC

Alphamab Oncology Doses First Patient in Phase III Trial of JSKN033 – World's First High‑Concentration Subcutaneous HER2 ADC/PD‑L1 Fixed‑Dose Combination for Recurrent Cervical Cancer
CompanyDrug

Alphamab Oncology Doses First Patient in Phase III Trial of JSKN033 – World’s First High‑Concentration Subcutaneous HER2 ADC/PD‑L1 Fixed‑Dose Combination for Recurrent Cervical Cancer

Hengrui Secures Dual NMPA Clinical Trial Approvals – KAT6 Inhibitor HRS-2189 Advances in Prostate Cancer, HRS-8046 Targets KRAS G12D Solid Tumors
CompanyDrug

Hengrui Secures Dual NMPA Clinical Trial Approvals – KAT6 Inhibitor HRS-2189 Advances in Prostate Cancer, HRS-8046 Targets KRAS G12D Solid Tumors

Enhertu Wins EU Approval in Resected HER2-Positive Breast Cancer – Daiichi Sankyo's ADC Cuts Recurrence Risk by 53% Versus T-DM1
CompanyDrug

Enhertu Wins EU Approval in Resected HER2-Positive Breast Cancer – Daiichi Sankyo’s ADC Cuts Recurrence Risk by 53% Versus T-DM1

Astellas Inks Exclusive Option and License Deal for Audax's DAX-044 – Up to USD 1.3 Billion to Back Tumor-Targeted IL-12 Immunotherapy
CompanyDeals

Astellas Inks Exclusive Option and License Deal for Audax’s DAX-044 – Up to USD 1.3 Billion to Back Tumor-Targeted IL-12 Immunotherapy

Show More